| abstract |
A human anti-NGF neutralizing antibody as a selective NGF pathway inhibitor is provided. The present invention provides antibodies that interact or bind to human nerve growth factor (NGF), thereby neutralizing the function of NGF. The present invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, particularly for treating NGF-related disorders (eg, chronic pain) by administering a pharmaceutically effective amount of an anti-NGF antibody. To do. A method for detecting the amount of NGF in a sample using an anti-NGF antibody is also provided. The invention also provides cells that produce the monoclonal antibodies of the invention, most preferably secreted into the cell culture medium. In addition to use in the treatment and management of pain, the antibodies of the invention are useful for the treatment of neuropathic and inflammatory pain-related responses. [Selection figure] None |